Skip to main content

Heart Failure clinical trials at UCSF
22 in progress, 10 open to eligible people

  • Apogee, A HeartWare HVAD Destination Product Surveillance Registry (PSR) Platform

    open to eligible people ages 18 years and up

    Medtronic is sponsoring the Apogee study to further enhance scientific understanding of the implant procedure, optimized blood pressure management, and anticoagulation/ antiplatelet therapy in patients receiving a Medtronic HeartWare™ Ventricular Assist Device (HVAD™) for destination therapy. The Apogee study is conducted within Medtronic's Product Surveillance Platform.

    San Francisco, California and other locations

  • Cardiac Recovery Through Dietary Support

    open to eligible people ages 18 years and up

    This is a prospective, randomized, wait-list controlled study examining the impact of providing medically appropriate meals to patients discharged from Zuckerberg San Francisco General Hospital after acute decompensated heart failure. Upon discharge, patients will be randomized to either the intervention or wait list control arm. The intervention is the delivery of medically appropriate meals and groceries to patients' homes in a tapered manner over five months (the equivalent of three meals a day for 60 days, then the equivalent of two meals a day for 30 days, then the equivalent of one meal a day for 60 days) and monthly assessments with a registered dietician (RD). All food and RD assessments are administered via a community partner, Project Open Hand, as a modification of current offerings for clients at Project Open Hand. Subjects randomized into the wait list control arm will receive the food intervention five months after discharge. The study's primary aim is to examine the impact of nutritional support on the Kansas City Cardiomyopathy Questionnaire scores. In addition, the study aims to examine the impact of nutritional support on healthcare utilization (particularly readmission rates and emergency room utilization), dietary change, medication adherence, and quality of life.

    San Francisco, California

  • Destination Therapy Post Approval Study

    open to eligible people ages 18 years and up

    Medtronic is sponsoring the HeartWare™ HVAD™ Destination Therapy (DT) Post Approval Study (PAS) to further confirm safety and effectiveness of the HeartWare Ventricular Assist Device System (HVAD System) when used as intended, in "real-world" clinical practice. The Destination Therapy Post Approval Study (DT PAS) is conducted within Medtronic's Product Surveillance Platform.

    San Francisco, California and other locations

  • EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

    open to eligible people ages 18 years and up

    The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction

    Fresno, California and other locations

  • INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

    open to eligible people ages 18 years and up

    INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.

    San Francisco, California and other locations

  • Mechanical Support Measures of Adjustment and QOL

    open to eligible people ages 19 years and up

    The purpose of this study is to develop a measurement system to assess adjustment to mechanical circulatory support (MCS) (also referred to as a ventricular assist device [VAD]) and health-related quality of life (HRQOL) in patients with advanced heart failure who receive a VAD. This investigators refer to this measurement system as Mechanical Circulatory Support: Adjustment and Quality of Life (MCS A-QOL).

    San Francisco, California and other locations

  • Multiple Cardiac Sensors for the Management of Heart Failure

    open to eligible people ages 18 years and up

    The MANAGE-HF study is a multi-center, global, prospective, open label, multi-phase trial intended to evaluate the clinical efficacy of the HeartLogic heart failure diagnostic feature.

    San Francisco, California and other locations

  • Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF..

    San Francisco, California and other locations

  • Remote Dielectric Sensing (ReDS) Assisted Diuresis in Acute Decompensated Heart Failure

    open to eligible people ages 18 years and up

    This study evaluates the use of a wearable vest capable of non-invasively measuring lung fluid content in hospitalized patients with heart failure

    San Francisco, California

  • The Product Surveillance Registry REVERSE Post Approval Study

    open to all eligible people

    The purpose of the REVERSE Post Approval Study (PAS) is to confirm the benefit observed in the REVERSE and RAFT pivotal studies in "real-world" clinical practice.

    San Francisco, California and other locations

  • A Study AnalyZing a NovEl Wearable SeNsor for Remote PatIent Health Monitoring

    Sorry, accepting new patients by invitation only

    Evaluate the performance of the CorBand product when used to monitor patients.

    San Francisco, California

  • Addressing Social Vulnerabilities in Cardiovascular Disease

    Sorry, not yet accepting patients

    The investigators will conduct a feasibility study of an enhanced transitional care intervention, that will: 1) automate identification and risk-stratification of patients with CHF and IHD with social vulnerabilities; 2) incorporate a new standardized social vulnerabilities screening tool into clinical care; 3) enable electronic referrals to community resources; and 4) add novel community-based interventions to the existing medically-oriented transitional care intervention that is the standard of care at the study hospital (Parkland Hospital in Dallas, Texas) and other hospitals nationwide.

  • Attain Performa™ Left Ventricular (LV) Quadripolar Leads Chronic Performance Study

    Sorry, in progress, not accepting new patients

    Lead survivability will be summarized.

    San Francisco, California and other locations

  • Baroreflex Activation Therapy for Heart Failure

    Sorry, not currently recruiting here

    The purpose of this clinical trial (NCT02627196) is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy with the BAROSTIM NEO System in subjects with heart failure, defined as New York Heart Association (NYHA) functional Class III, left ventricular ejection fraction (LVEF) ≤ 35% and NT-proBNP<1600 pg/ml despite being treated with the appropriate heart failure guideline directed therapy, excluding subjects eligible for or actively receiving Cardiac Resynchronization Therapy (CRT). The total trial duration is anticipated to be approximately 5 years; however, the duration of an individual subject enrollment will depend on when he or she entered the trial.

    Fresno, California and other locations

  • Dynamic Heart Failure Prediction With Real-time Functional Status Data in the Ambulatory Setting

    Sorry, not yet accepting patients

    Heart failure is the number one cause of hospital readmission in those over 65 years of age and the current standard-of-care of weight self-monitoring is inadequate to predict exacerbation. This project aims to improve the monitoring of heart failure disease progression through the use of real-time, up-to-date data obtained both from a smart phone-based tool and from the electronic health record. The goal is to develop a low-risk, clinically validated method to estimate dynamic heart failure risk to enable the provision of earlier, more effective outpatient interventions that decrease hospitalization.

    San Francisco, California

  • Home Outpatient Monitoring and Engagement to Predict HF Exacerbation

    Sorry, accepting new patients by invitation only

    The HOME PREDICT HF study looks at new ways to predict hospitalizations for heart failure. We will use a set of devices at home and surveys to collect information about patient's health. This study uses the Eureka app, a new study app developed by the University of California, San Francisco. The study is designed to happen remotely, using this application on a patient's smartphone, so that is as convenient as possible to participate.

    San Francisco, California

  • HW006 LATERAL Thoracotomy

    Sorry, in progress, not accepting new patients

    This is a prospective, multi-center,single-arm study that will evaluate the thoracotomy implant technique in up to 145 subjects implanted via thoracotomy with the HeartWare HVAD System and enrolled in the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs®) protocol and database. All participating centers are current INTERMACS® sites in good standing and follow the INTERMACS® protocol and procedures.

    San Francisco, California and other locations

  • Model 4296 Left Ventricular (LV) Lead Chronic Performance Study

    Sorry, in progress, not accepting new patients

    Lead survivability will be summarized.

    San Francisco, California and other locations

  • Model 4396 Left Ventricular (LV) Lead Chronic Performance Study

    Sorry, in progress, not accepting new patients

    Lead survivability will be summarized.

    San Francisco, California and other locations

  • Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

    Sorry, in progress, not accepting new patients

    This study is a prospective, multi-center, randomized, double-blind placebo-controlled study of subjects receiving the HM II LVAD as per the current FDA approved indications for use.

    San Francisco, California and other locations

  • PRODIGY Registry in NYHA Class III Heart Failure Patients

    Sorry, not currently recruiting here

    This is an observational, prospective, single arm, multi-center registry to evaluate the Cordella™ Heart Failure System (CHFS) in up to 250 NYHA Class III HF patients .

    San Francisco, California and other locations

  • Use of 3-D Blood Pool Scintigraphy to Guide Left Ventricular Pacing Lead Placement in Patients Requiring Cardiac Resynchronization Therapy

    Sorry, in progress, not accepting new patients

    The purpose of this study is to determine whether multiple gated acquisition (MUGA) guided lead placement improves clinical outcomes for patients needing cardiac resynchronization therapy (CRT) compared to traditional posterolateral left ventricular lead placement.

    San Francisco, California

Last updated: